Bristol-Myers Squibb and Vedanta Biosciences to Evaluate Opdivo and VE800 in Patients with Advanced or Metastatic Cancers

Bristol-Myers Squibb and Vedanta Biosciences to Evaluate Opdivo and VE800 in Patients with Advanced or Metastatic Cancers

Source: 
CP WIre
snippet: 
  • VE800, is based on work showing in preclinical models that certain gut-dwelling bacterial strains potentiate cytotoxic CD8+ T cells and enhance infiltration into tumors
  • Bristol-Myers Squibb currently intends to make an equity investment in Vedanta Biosciences